After coming out of the quiet period, Morgan Stanley initiates Chimerix (CMRX -0.2%) with an...

|About: Chimerix Inc (CMRX)|By:, SA News Editor

After coming out of the quiet period, Morgan Stanley initiates Chimerix (CMRX -0.2%) with an Overweight rating and a $26.00 price target. Morgan says the company is developing CMX001, a drug for the treatment of a broad range of dsDNA viruses, which has all the bells and whistles to be a blockbuster with best in disease potential, including having important impact on high acuity points and fulfilling a clear unmet need. Additionally, Cowen starts the shares with an Outperform and Lazard with a Buy.